RTA 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Probst, Brandon L ^a   Trevino, Isaac ^a   McCauley, Lyndsey ^a   Bumeister, Ron ^a,b   Dulubova, Irina ^a   Wigley, W Christian ^a   Ferguson, Deborah A ^a  

^a Reata Pharmaceuticals Inc   (United States)

^b SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BARDOXOLONE METHYL; CASPASE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; RTA 408; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG; AUTACOID; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; N-(11-CYANO-2,2,6A,6B,9,9,12A-HEPTMETHYL-10,14-DIOXO-1,3,4,5,6A,6B,7,8,8A,9,10,12A,14,14A,14B-HEXADECAHYDRO-2H-PICEN-4A-YL)-2-2-DIFLUOROPROPIONAMIDE; NFE2L2 PROTEIN, HUMAN; TRITERPENE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; NONHUMAN; ANIMAL; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; GENETICS; IC50; METABOLISM; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; INFLAMMATION MEDIATORS; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE 4; MICE; NF-E2-RELATED FACTOR 2; NF-KAPPA B; TRITERPENES;

EID: 84928169482     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122942     Document Type: Article

References (55)

1. Liu J. Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 2005 Aug 22; 100(1-2):92-4. PMID: 16125023
2. Reisman SA, Aleksunes LM, Klaassen CD. Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. Biochem Pharmacol 2009 Apr 1; 77(7):1273-82. PMID: 19283895
3. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005 Mar 22; 102(12):4584-9. PMID: 15767573
4. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999 Jan 1; 13(1):76-86. PMID: 9887101
5. Cleasby A, Yon J, Day PJ, Richardson C, Tickle IJ, Williams PA, et al. Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO. PLoS ONE 2014; 9(6):e98896. doi: 10.1371/journal.pone.0098896 PMID: 24896564
6. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006 Apr 1; 116(4):984-95. PMID: 16585964
7. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 2011 Apr; 85(4):241-72. doi: 10.1007/s00204-011-0674-5 PMID: 21365312
8. Yates M, Tran Q, Dolan P, Osburn W, Shin S, McCulloch C, et al. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 2009; 30(6):1024-55. doi: 10.1093/carcin/bgp100 PMID: 19386581
9. Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 2012 Oct; 64(4):972-1003. doi: 10.1124/pr.111.004846 PMID: 22966038
10. Wang YY, Zhe H, Zhao R. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol Cancer 2014; 13:30. doi: 10.1186/1476-4598-13-30 PMID: 24552536
11. Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 2006 Mar 15; 12(6):1828-38. PMID: 16551868
12. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me Blocks the NF-{kappa}B Pathway by Direct Inhibition of IKKbeta on Cys-179. J Biol Chem 2006 Nov 24; 281(47):35764-9. PMID: 16998237
13. Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid 1-[2-cyano-3,12-diox-ooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-{kappa}B activation through direct inhibition of I{kappa}B kinase {beta}. Mol Cancer Ther 2006 Dec; 5(12):3232-9. PMID: 17148759
14. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 2004 Oct 15; 64 (20):7570-8. PMID: 15492284
15. Ahmad R, Raina D, Meyer C, Kufe D. Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res 2008 Apr 15; 68(8):2920-6. doi: 10.1158/0008-5472.CAN-07-3036 PMID: 18413761
16. Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2006 Jul 15; 12(14 Pt 1):4288-93. PMID: 16857804
17. Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, et al. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2006 Feb; 5(2):317-28. PMID: 16505105
18. Zou W, Yue P, Khuri FR, Sun SY. Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res 2008 Sep 15; 68(18):7484-92. doi: 10.1158/0008-5472.CAN-08-1318 PMID: 18794136
19. Zou W, Chen S, Liu X, Yue P, Sporn MB, Khuri FR, et al. c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biol Ther 2007 Oct; 6(10):1614-20. PMID: 18253090
20. Townson JL, Macdonald IC, Liby KT, Mackenzie L, Dales DW, Hedley BD, et al. The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. Clin Exp Metastasis 2011 Jan 15.
21. Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 1999 Jan 15; 59(2):336-41. PMID: 9927043
22. Vannini N, Lorusso G, Cammarota R, Barberis M, Noonan DM, Sporn MB, et al. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Mol Cancer Ther 2007 Dec; 6 (12):3139-46. PMID: 18065492
23. Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, et al. The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res 2007 May 1; 67(9):4210-8. PMID: 17483332
24. Hiramoto K, Satoh H, Suzuki T, Moriguchi T, Pi J, Shimosegawa T, et al. Myeloid lineage-specific deletion of antioxidant system enhances tumor metastasis. Cancer Prev Res (Phila) 2014 Aug; 7(8):835-44. doi: 10.1158/1940-6207.CAPR-14-0094 PMID: 24866179
25. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010 Mar 15; 16(6):1812-23. doi: 10.1158/1078-0432.CCR-09-3272 PMID: 20215551
26. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002 Jan 1; 99 (1):326-35. PMID: 11756188
27. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, et al. A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res 2012 May 25.
28. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Ward KW. Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin. Arch Dermatol Res 2014 Jul; 306(5):447-54. doi: 10.1007/s00403-013-1433-7 PMID: 24362512
29. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW. Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis. Radiat Res 2014 May; 181 (5):512-20. doi: 10.1667/RR13578.1 PMID: 24720753
30. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008 Mar 1; 68(5):1303-9. doi: 10.1158/0008-5472.CAN-07-5003 PMID: 18316592
31. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 2008 Apr; 28 (8):2758-70. doi: 10.1128/MCB.01704-07 PMID: 18268004
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 Dec; 25(4):402-8. PMID: 11846609
33. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990 Jul 4; 82(13):1107-12. PMID: 2359136
34. Carrasco RA, Stamm NB, Patel BK. One-step cellular caspase-3/7 assay. Biotechniques 2003 May; 34 (5):1064-7. PMID: 12765032
35. Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, Sporn MB. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998 Oct 6; 8(19):2711-4. PMID: 9873608
36. Thimmulappa RK, Scollick C, Traore K, Yates M, Trush MA, Liby KT, et al. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem Biophys Res Commun 2006 Oct 30; 351:883-9. PMID: 17097057
37. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009 Apr; 34(4):176-88. doi: 10.1016/j.tibs.2008.12.008 PMID: 19321346
38. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal 2010 Dec 1; 13(11):1627-37. doi: 10.1089/ars.2010.3219 PMID: 20446773
39. Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003 Sep 15; 63(18):5926-39. PMID: 14522919
40. Kim EH, Deng CX, Sporn MB, Williams CR, Royce DB, Risingsong R, et al. CDDO-Methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prev Res (Phila) 2011 Sep 20.
41. Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K. The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev Res (Phila) 2012 May; 5(5):726-34. doi: 10.1158/1940-6207.CAPR-11-0404 PMID: 22401982
42. Ikeda T, Sporn M, Honda T, Gribble GW, Kufe D. The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 2003 Sep 1; 63(17):5551-8. PMID: 14500394
43. Honda T, Rounds BV, Bore L, Favaloro FG Jr., Gribble GW, Suh N, et al. Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1999 Dec 20; 9(24):3429-34. PMID: 10617085
44. Slocum SL, Kensler TW. Nrf2: control of sensitivity to carcinogens. Arch Toxicol 2011 Apr; 85(4):273-84. doi: 10.1007/s00204-011-0675-4 PMID: 21369766
45. Rachakonda G, Sekhar KR, Jowhar D, Samson PC, Wikswo JP, Beauchamp RD, et al. Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene 2010 Jun 24; 29(25):3703-14. doi: 10.1038/onc.2010.118 PMID: 20440267
46. Thangasamy A, Rogge J, Krishnegowda NK, Freeman JW, Ammanamanchi S. Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor-mediated cancer cell invasion. J Biol Chem 2011 Sep 16; 286(37):32115-22. doi: 10.1074/jbc.M111.245746 PMID: 21799005
47. Satoh H, Moriguchi T, Taguchi K, Takai J, Maher JM, Suzuki T, et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 2010 May 31.
48. Lu T, Gabrilovich DI. Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin Cancer Res 2012 Sep 15; 18(18):4877-82. doi: 10.1158/1078-0432.CCR-11-2939 PMID: 22718858
49. Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2004 Apr 15; 103(8):3158-66. PMID: 15070698
50. Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, et al. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) 2010 Nov; 3 (11):1427-34. doi: 10.1158/1940-6207.CAPR-10-0197 PMID: 20959520
51. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012 Aug; 12(8):564-71. doi: 10.1038/nrc3278 PMID: 22810811
52. Kensler T, Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis 2010; 31(1):90-9. doi: 10.1093/carcin/bgp231 PMID: 19793802
53. Niture SK, Jaiswal AK. INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis. Cell Death Differ 2011 Mar; 18(3):439-51. doi: 10.1038/cdd.2010.114 PMID: 20865015
54. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 2009 Oct 9; 36(1):131-40. doi: 10.1016/j.molcel.2009.07.025 PMID: 19818716
55. Thu KL, Pikor LA, Chari R, Wilson IM, Macaulay CE, English JC, et al. Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer. J Thorac Oncol 2011 Sep; 6(9):1521-9. doi: 10.1097/JTO.0b013e3182289479 PMID: 21795997